GIT Regulators, Antiflatulents & Anti-inflammatories
| Drug | Dosage | Remarks |
|---|---|---|
| Prucalopride | 1-2 mg PO 24 hourly | Adverse Reactions
|
Laxatives, Purgatives
| Drug1 | Available Strength | Dosage | Remarks |
|---|---|---|---|
| Bulk-producing Laxatives | |||
|
Ispaghula (Ispaghula husk, Plantago ovata seed shells, Psyllium) |
3.25 g/5 g sachet | 1 sachet in >150 mL liquid PO 8-24 hourly |
Adverse Reactions
|
| 3.5 g/sachet | |||
| 5 g/sachet | |||
| 6 g/sachet | |||
| Methylcellulose | Powder | 2 g in liquid PO as single dose May increase to 2 g PO 8 hourly |
|
| Contact Laxatives (Stimulant Laxatives) | |||
| Bisacodyl | 5 mg/tab | 1-2 tab PO 24 hourly at bedtime |
Adverse Reactions
|
| 10 mg/suppository | 1 suppository rectally 24 hourly | ||
| Castor oil | 4.4 mL/5 mL | 45 mL PO 24 hourly | |
| Glycerol (Glycerin) | 2.5 g suppository | 1 suppository rectally as required | |
| Sodium picosulfate | 4 mg/5 mL | 10-20 mL PO 24 hourly at bedtime | |
| 5 mg/5 mL | 5-10 mg PO 24 hourly at bedtime | ||
| 7.5 mg/mL | 10-20 drops PO at bedtime | ||
| 8 mg/tab | 1-2 tab PO 24 hourly at bedtime | ||
| Standardized senna concentrate | 187 mg/tab | 2 tab PO 24 hourly, may increase to 4 tab PO 12 hourly | |
| 325 mg/cap | 2 cap PO 24 hourly at bedtime | ||
| 374 mg/tab | 1-2 tab PO 24 hourly, may increase to 2 tab PO 12 hourly | ||
| 450 mg/cap | 1 cap PO 1 hour after breakfast | ||
| Senna alexandrina: 400 mg/cap |
2-3 cap PO 24 hourly before bedtime | ||
| Sennosides A and B: 7.5 mg/tab | 2-4 tab PO 24 hourly at bedtime | ||
| Sennosides A and B: 8.77 mg/tab | 2 tab PO 24 hourly. may increase to 4 tab PO 12 hourly | ||
| Sennosides A and B: 17.54 mg/tab | 1-2 tab PO 24 hourly, may increase to 2 tab PO 12 hourly | ||
| Sennoside B: 7.5 mg/tab |
1-4 tab PO 24 hourly at bedtime | ||
| Sennoside B: 16 mg/tab |
1-2 tab PO 24 hourly | ||
| Osmotically Acting Laxatives | |||
| Lactitol monohydrate | 10 g/15 mL | 15-30 mL PO 24 hourly |
Adverse Reactions
|
| Lactulose | 3.3 g/5 mL |
Initial dose: 15-45 mL PO 24 hourly or divided 12 hourly Maintenance dose: 10-30 mL PO 24 hourly Max dose: 60 mL/day |
|
| 3.43 g/5 mL | |||
| 9.9 g/15 mL | |||
| 10 g/15 mL | |||
|
66.7 g/100 mL, 667 g/L, 667 mg/mL |
|||
| 670 mg/mL | |||
| Macrogol (Polyethylene glycol) | 4,000 powder | 10-20 g PO 24 hourly | |
| 3,350 powder | 17 g PO 24 hourly | ||
| Magnesium hydroxide (Mg [OH]2, Milk of Magnesia) | 400 mg/5 mL | 15-60 mL PO at bedtime or upon arising | |
| 800 mg/5 mL | 10-30 mL PO 24 hourly at bedtime or in divided doses | ||
| 8 g/100 mL | 30-45 mL PO at bedtime or morning after waking | ||
| Monosodium phosphate/Disodium phosphate (Monobasic Na phosphate/Dibasic Na phosphate, Sodium biphosphate/Sodium phosphate) |
Oral solution | 20-45 mL PO 24 hourly | |
| Rectal solution | 133 mL (1 bottle) rectally 24 hourly or as directed | ||
| Sodium chloride (NaCl) | 15% rectal solution | 20-40 mL rectally as required | |
| Sorbitol | 5 g/sachet | 2 sachets PO at bedtime and 1 sachet PO before breakfast | |
| 70% oral solution | 30-45 mL (27-40 g) PO 24 hourly | ||
| 25-30% rectal solution | 120 mL rectally as an enema 24 hourly | ||
| Softeners, Emollient Laxatives1 | |||
| Docusate sodium | 20 mg/5 mL oral liquid |
15-60 mL PO 24 hourly or in divided doses |
Adverse Reactions
Special Instructions
|
| 50 mg/5 mL oral solution | 100 mg PO 8 hourly Max dose: 500 mg/day in divided doses |
||
| Paraffin (Liquid paraffin) | 2.5 mL/5 mL | 10-20 mL PO when required before bedtime |
Adverse Reactions
|
| 4.83 mL/15 mL oral emulsion | 15-30 mL PO when required before bedtime | ||
| Other Drugs for Constipation | |||
| Elobixibat | 5 mg/tab |
10 mg PO 24 hourly Max dose: 15 mg/day |
Adverse Reactions
|
| Lubiprostone | 24 mcg/cap | 24 mcg PO 12 hourly |
Adverse Reactions
|
| 1Various combination products are available. Please see the latest MIMS for specific formulations and prescribing information. | |||
Neuromuscular Disorder Drugs
| Drug | Dosage | Remarks |
|---|---|---|
| Distigmine bromide |
Chronic hypotonic constipation: Initial dose: 2.5 mg PO 24 hourly May increase in increments of 2.5 mg every 3 days Max dose: 10 mg/day Continue treatment until normal intestinal function has been restored (10-14 days) |
Adverse Reactions
|
| Neostigmine methylsulfate |
Atonic constipation: 0.5-2.5 mg SC or IM 24 hourly |
|
| Pyridostigmine bromide |
Atonic constipation: 60 mg PO 4 hourly |
Other Gastrointestinal Drugs
| Drug | Dosage | Remarks |
|---|---|---|
| Linaclotide | 72-145 mcg PO 24 hourly | Adverse Reactions
|
Supplements & Adjuvant Therapy
| Drug | Dosage | Remarks |
|---|---|---|
| Bifidobacterium lactis1 BB-12 | 1 g PO 24 hourly | Special Instructions
|
| Partially hydrolyzed cyamopsis tetragonoloba gum (Partially hydrolyzed guar gum) | 6 g PO 24 hourly |
Special Instructions
|
| Lactic acid-producing Organisms | ||
| Lactobacillus acidophilus2 | 1-4 cap or tab PO 8-24 hourly or 1-2 sachet PO 8-24 hourly |
Special Instructions
|
| Lactobacillus reuteri | 1-2 tab PO 24 hourly or 1-2 sachet PO 24 hourly | Special Instructions
|
| Lactobacillus sporogenes | 4 tab PO 8 hourly or 4 sachets PO 8 hourly | Special Instructions
|
| 1Various combination products for Bifidobacterium sp are available. Please see the latest MIMS for specific formulations and prescribing information. 2Various combination products are available. Please see the latest MIMS for specific formulations and prescribing information. |
||
Disclaimer
All dosage recommendations are for non-pregnant and non-breastfeeding women, and non-elderly adults with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
